OCT 12, 2017 09:00 AM PDT
Circulating biomarkers - what matters for the isolation of biomarkers from Liquid Biopsy samples
Presented at the Cancer Research & Oncology 2017 Virtual Event
SPONSORED BY: QIAGEN Molecular Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 1 22

Speakers:
  • Global Product Manager, QIAGEN
    Biography
      Dr. Verena Schramm is a Global Product Manager for RNA sample extraction and Liquid Biopsy at QIAGEN GmbH, Germany. Before taking over these product responsibility, she was a Global Product Manager for NGS library preparation products at QIAGEN.
      Verena holds and M.Sc. in Molecular Biology and a PhD in Bioinformatics. During her PhD at EMBL Heidelberg she studied the impact of copy-number variation during the evolution of non-human primates using Next-Generation Sequencing.
      Before joining QIAGEN, Verena worked as a Sales and Business Development Manager DACH, NL and as a Subject Matter Expert at Sophia Genetics a company focusing on the analysis of clinical NGS data in Diagnostics.

    Abstract:

    The analysis of circulating biomarkers in a patient’s blood holds significant potential for early disease detection and disease monitoring. Circulating DNA is the most commonly studied biomarker in the context of Liquid Biopsy research. However, in the last couple of years, free-circulating RNA has gained more attention for biomarker analysis and interpretation.

    In this webinar, we will discuss the different types of circulating RNA biomarkers studied in Liquid Biopsy samples. A special focus will be given to the challenges and solutions for circulating RNA isolation.


    Show Resources
    Loading Comments...